[go: up one dir, main page]

EP3843747A1 - Traitement à la taurolidine pour des tumeurs exprimant des gènes myc dans des corps de mammifère - Google Patents

Traitement à la taurolidine pour des tumeurs exprimant des gènes myc dans des corps de mammifère

Info

Publication number
EP3843747A1
EP3843747A1 EP19854097.3A EP19854097A EP3843747A1 EP 3843747 A1 EP3843747 A1 EP 3843747A1 EP 19854097 A EP19854097 A EP 19854097A EP 3843747 A1 EP3843747 A1 EP 3843747A1
Authority
EP
European Patent Office
Prior art keywords
composition
taurinamide
taurultam
dosage range
taurolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19854097.3A
Other languages
German (de)
English (en)
Other versions
EP3843747A4 (fr
Inventor
Bruce Reidenberg
Robert Diluccio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cormedix Inc
Original Assignee
Cormedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cormedix Inc filed Critical Cormedix Inc
Publication of EP3843747A1 publication Critical patent/EP3843747A1/fr
Publication of EP3843747A4 publication Critical patent/EP3843747A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • This invention relates to therapeutic methods and compositions in general, and more particularly to therapeutic methods and compositions for the treatment of MYC-expressing tumors in mammalian bodies.
  • Taurolidine is a well known antimicrobial with a published mechanism of action and antimicrobial
  • Taurolidine is unstable in circulation and therefore has not been successfully developed for systemic infections. Taurolidine has demonstrated efficacy in local application for peritonitis and for prevention of infection when used as a catheter-lock solution .
  • Taurolidine has recently been investigated for oncolytic activity and found to have an inhibitory effect on cell lines in culture, in combination with standard chemotherapy or alone. Despite claims that in vitro inhibitory concentrations are clinically achievable, the only published human pharmacokinetic study showed NO measurable concentration of
  • taurolidine in healthy volunteers when 5 grams of taurolidine were given intravenously by 20 minute infusion. This is believed to be due to the rapid hydrolysis of taurolidine when administered
  • MYC oncogenes have been widely described in solid tumors and in lymphoma/ leukemia .
  • CORMEDIX-35 Taurolidine has demonstrated efficacy in treating neuroblastoma in a laboratory cell line. This cell line is known to overexpress N-myc genes.
  • Taurolidine has demonstrated efficacy in treating ovarian cancer in a human ovarian cell tumor line implanted in mice. This cell line is known to overexpress C-myc genes.
  • Taurolidine has demonstrated efficacy in treating lung cancer in a laboratory cell line. This cell line is known to overexpress L-myc genes.
  • taurolidine and/or the hydrolysis products of taurolidine, is/are used to treat tumors that
  • N-myc genes overexpress N-myc genes, C-myc genes and/or L-myc genes in mammalian bodies.
  • tumors that may overexpress N-myc genes, C-myc genes and/or L-myc
  • CORMEDIX-35 genes include, but are not limited to, lymphoma, melanoma, multiple myeloma, neuroblastoma, colon, breast and lung cancers.
  • the preferred hydrolysis products of taurolidine may comprise at least one from the group consisting of :
  • taurultam, taurinamide and methylene glycol in a ratio of 1 taurultam: 7 taurinamide : 1 methylene glycol.
  • the taurolidine is given with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range between 5 mg/kg and 60 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
  • the taurultam is given with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range between
  • the taurinamide is given with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range between 5 mg/kg and 60 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
  • the methylene glycol is given with a dosage range of from 2.5 mg/kg to 160 mg/kg, with optimal range between 2.5 mg/kg and 30 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
  • the taurultam and taurinamide (in a ratio of 1 taurultam:7 taurinamide) is given with a dosage range of taurultam from 5 mg/kg to 280 mg/kg, with optimal range between 5 mg/kg and 40 mg/kg, combined with taurinamide with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range from 35 mg/kg to 40 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
  • taurultam, taurinamide and methylene glycol (in a ratio of 1 taurultam: 7 taurinamide : 1 methylene glycol) is given with a dosage range of taurultam from 5 mg/kg to 280 mg/kg, with optimal range between 5 mg/kg and 40 mg/kg, combined with taurinamide with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range from 35 mg/kg to 40 mg/kg, further combined with methylene glycol with a dosage range of from 2.5 mg/kg to 160 mg/kg with optimal range from 5 mg/kg to 40 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
  • the taurolidine, and/or the hydrolysis products of taurolidine can be given systemically, preferably intramuscularly or intravenously.
  • the taurolidine, and/or the hydrolysis products of taurolidine is/are delivered systemically in a
  • taurolidine or the hydrolysis products of taurolidine, can reach the site of the tumor without premature degradation, whereupon
  • taurolidine can treat the tumor.
  • the taurolidine and/or the hydrolysis products of taurolidine can be delivered in the form of a nanoparticle, where the nanoparticle comprises a core of the taurolidine and/or the hydrolysis products of taurolidine and an exterior coating which is configured to prevent premature exposure of the taurolidine and/or the hydrolysis products of
  • the exterior coating breaks down as the nanoparticle travels from the site of the insertion to the site of the tumor so as to release the taurolidine and/or the hydrolysis products of taurolidine intact at the site of the tumor.
  • the coating comprises an absorbable polymer or lipid which breaks down as the nanoparticle travels from the site of insertion to the site of the tumor.
  • the taurolidine and/or the hydrolysis products of taurolidine may be delivered using a polymer system which is configured to delay premature degradation of the active ingredient.
  • the taurolidine and/or the hydrolysis products of taurolidine may be "pegylated” using polyethylene glycols (PEGs) to delay premature degradation of the active ingredient.
  • taurolidine, and/or the hydrolysis products of taurolidine may be delivered as either a single agent or in combination with other oncolytic agents and/or radiotherapy.
  • Fig. 1 is a graph showing that leukemia cell lines appear more sensitive to the effects of
  • taurolidine compared to healthy lymphocytes in vitro ( not in vivo ) ;
  • Fig. 2 is a graph showing that neuroblastoma cell lines are more sensitive to a decrease in viability due to taurolidine when compared to healthy
  • Figs. 3-6 are graphs or photographs showing that taurolidine given to CB57 SCID mice with measurable tumors from a neuroblastoma cell line implanted subcutaneously in the CB57 SCID mice has efficacy in IMR5 tumors and measurable efficacy in SK-N-AS tumors in vivo (not in vitro) ;
  • Figs. 7 and 8 are graphs showing that
  • Fig. 9 is a chart showing the effect of delayed administration of a single 3-day i.p.
  • taurolidine (20 mg/mouse/in ection) on the occurrence of i.p. human tumor xenografts in female nude mice after the i.p. administration of 5 x 10 6 SKOV-3 human ovarian tumor cells;
  • Fig. 10 illustrates the mechanism for the hydrolysis of taurolidine
  • Fig. 11 is a chart showing the mean
  • Fig. 12 is a chart showing the mean
  • Taurolidine was developed as an anti-infective, but has been found to have oncolytic activity against neuroblastoma tumors in a laboratory cell line. This laboratory cell line is known to overexpress N-myc
  • taurolidine has been found to have surprising oncolytic activity in cell cultures of human cancer cells expressing N-myc, and now in a rodent cancer model based on an N-myc expressing human cancer cell line.
  • neuroblastoma cell lines are more sensitive to a decrease in viability due to taurolidine when compared to healthy
  • taurolidine given to CB57 SCID mice with measurable tumors from a neuroblastoma cell line implanted subcutaneously in the CB57 SCID mice showed dramatic efficacy in IMR5 tumors and measurable efficacy in SK-N-AS tumors in vivo (not in vitro) .
  • CORMEDIX-35 treat mice with a different cell line (SK-N-AS) also derived from neuroblastoma, though overall survival of the mice implanted with the tumor was not
  • Taurolidine has also demonstrated efficacy in treating ovarian cancer in a human ovarian cell tumor line implanted in mice.
  • This cell line is known to overexpress C-myc genes.
  • Fig. 9 shows the effect of delayed administration of a single 3-day i.p. ( intraperitoneal ) bolus injection regimen of taurolidine (20 mg/mouse/in ection) on the occurrence of i.p. human tumor xenografts in female nude mice after the i.p. administration of 5 x 10 6 SKOV-3 human ovarian tumor cells.
  • taurolidine therapy was initiated on the day of tumor cell
  • mice in all of the groups were sacrificed, and the peritoneal cavity was examined for the presence of tumors.
  • CORMEDIX-35 number of animals in each group ranged from 15-21 (Cancer Res., 2001 Sep 15; 61 ( 18 ) : 6816-21 ,
  • Taurolidine cytotoxic and mechanistic evaluation of a novel antineoplastic agent, Calabresi Pi, Goulette FA, Darnowski JW) .
  • Taurolidine has also demonstrated efficacy in treating lung cancer in a laboratory cell line.
  • This cell line is known to overexpress L-myc genes.
  • taurolidine is/are used to treat tumors that
  • N-myc genes overexpress N-myc genes, C-myc genes and/or L-myc genes in mammalian bodies.
  • tumors that may overexpress N-myc genes, C-myc genes and/or L-myc genes include, but are not limited to, lymphoma, melanoma, multiple myeloma, neuroblastoma, colon, breast and lung cancers.
  • Fig. 10 The mechanism for the hydrolysis of taurolidine is shown in Fig. 10.
  • the preferred hydrolysis products of taurolidine that may be used to treat tumors that overexpress N-myc genes, C-myc genes
  • CORMEDIX-35 and/or L-myc genes in mammalian bodies may comprise at least one from the group consisting of:
  • taurultam 7 taurinamide
  • taurultam, taurinamide and methylene glycol in a ratio of 1 taurultam: 7 taurinamide : 1 methylene glycol.
  • the taurolidine is given with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range between 5 mg/kg and 60 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
  • the taurultam is given with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range between 5 mg/kg and 60 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
  • the mean pharmacokinetic parameters of taurultam are shown in Fig. 11.
  • the taurinamide is given with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range between 5 mg/kg and 60 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
  • the mean pharmacokinetic parameters of taurinamide are shown in Fig. 12.
  • the methylene glycol is given with a dosage range of from 2.5 mg/kg to 160 mg/kg, with optimal range between 2.5 mg/kg and 30 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
  • the taurultam and taurinamide (in a ratio of 1 taurultam:7 taurinamide) is given with a dosage range of taurultam from 5 mg/kg to 280 mg/kg, with optimal range between 5 mg/kg and 40 mg/kg, combined with taurinamide with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range from 35 mg/kg to 40 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
  • CORMEDIX-35 glycol is given with a dosage range of taurultam from 5 mg/kg to 280 mg/kg, with optimal range between 5 mg/kg and 40 mg/kg, from once daily through weekly, combined with taurinamide with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range from 35 mg/kg to 40 mg/kg, further combined with methylene glycol with a dosage range of from 2.5 mg/kg to 160 mg/kg with optimal range from 5 mg/kg to 40 mg/kg from once daily through weekly, for an effective period of time based on individual patient response.
  • AUC 0-inf Taurultam/AUC 0-inf Taurinamide 42.9/312.7
  • the target ratio when giving taurultam and taurinamide in combination is 0.14 or 1:7. And the target ratio when giving
  • CORMEDIX-35 taurultam and taurinamide and methylene glycol in combination is 1:7:1.
  • the taurolidine, and/or the hydrolysis products of taurolidine can be given systemically, preferably intramuscularly or intravenously.
  • taurolidine is/are delivered systemically in a
  • taurolidine can treat the tumor.
  • the taurolidine, and/or the hydrolysis products of taurolidine is/are delivered in the form of a nanoparticle, where the nanoparticle comprises a core comprising taurolidine and/or the hydrolysis products of taurolidine, and an exterior coating which is configured to prevent premature exposure of the taurolidine, and/or the hydrolysis products of
  • the exterior coating breaks down as the nanoparticle travels from the site of insertion to the site of the tumor so as to release the
  • the coating comprises an absorbable polymer or lipid which breaks down as the nanoparticle travels from the site of insertion to the site of the tumor.
  • the coating can be created from
  • the coating may also be associated with glycols such as polyethylene glycols (PEGs), which can either be linear or multi-arm structures.
  • PEGs polyethylene glycols
  • the nanoparticle may comprise an excipient (e.g., a buffer for providing enhanced hydrolytic stability of the taurolidine and/or
  • the nanoparticle can further comprise a coating, wherein the coating is configured to target the nanoparticle to the site of a tumor so as to improve the efficacy of the taurolidine and/or hydrolysis product for treatment of the tumor.
  • the coating comprises binding molecules which are configured to target delivery of the nanoparticle to specific tissue .
  • taurolidine may be delivered using a polymer system which is configured to delay premature degradation of the taurolidine, and/or the hydrolysis products of taurolidine, and/or to optimize the release properties of the taurolidine, and/or the hydrolysis products of taurolidine.
  • the taurolidine, and/or the hydrolysis products of taurolidine may be "pegylated” using polyethylene glycols (PEGs) to delay premature degradation of the taurolidine, and/or the hydrolysis products of
  • taurolidine and/or to optimize the release properties of the taurolidine, and/or the hydrolysis products of taurolidine .
  • the taurolidine (and/or the hydrolysis products of taurolidine) may be delivered as either a single agent or in combination with other oncolytic agents and/or radiotherapy.
  • oncolytic agents that can be combined with taurolidine and/or the hydrolysis products of taurolidine for systemic
  • CORMEDIX-35 delivery are platinum compounds (cisplatin,
  • alkylating agents cyclophosphamide, ifosfamide, melphalan, topoisomerase II inhibitor
  • vinca alkaloids vincristine
  • topoisomerase I inhibitors topotecan and irinotecan

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé pour le traitement d'un cancer qui entraîne une surexpression d'un quelconque parmi des gènes N-myc, des gènes C-myc et/ou des gènes L-myc dans un corps de mammifère, le procédé comprenant: l'administration d'une composition au corps de mammifère, la composition comprenant au moins un parmi le groupe constitué par la taurolidine; le taurultam; le taurinamide; méthylène glycol; taurultam et taurinamide dans un rapport de 1 taurultam: 7 taurinamide; et taurultam, taurinamide et méthylène glycol dans un rapport de 1 taurultam: 7 taurinamide: 1 méthylène glycol.
EP19854097.3A 2018-08-31 2019-09-03 Traitement à la taurolidine pour des tumeurs exprimant des gènes myc dans des corps de mammifère Pending EP3843747A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862725650P 2018-08-31 2018-08-31
PCT/US2019/049266 WO2020047530A1 (fr) 2018-08-31 2019-09-03 Traitement à la taurolidine pour des tumeurs exprimant des gènes myc dans des corps de mammifère

Publications (2)

Publication Number Publication Date
EP3843747A1 true EP3843747A1 (fr) 2021-07-07
EP3843747A4 EP3843747A4 (fr) 2022-12-28

Family

ID=69643283

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19854097.3A Pending EP3843747A4 (fr) 2018-08-31 2019-09-03 Traitement à la taurolidine pour des tumeurs exprimant des gènes myc dans des corps de mammifère

Country Status (7)

Country Link
EP (1) EP3843747A4 (fr)
JP (2) JP2021535167A (fr)
KR (1) KR20210054544A (fr)
CN (1) CN113226325A (fr)
AU (1) AU2019331913B2 (fr)
CA (1) CA3111100A1 (fr)
WO (1) WO2020047530A1 (fr)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9005856D0 (en) * 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
US7151099B2 (en) * 1998-07-31 2006-12-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
GB9716219D0 (en) * 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
AU784539B2 (en) * 1999-12-06 2006-04-27 Geistlich Pharma Ag Methods of treating tumors
CN100519525C (zh) * 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
US20030092707A1 (en) * 2001-10-19 2003-05-15 Redmond H. Paul Treatment of breast cancer
US20080171738A1 (en) * 2001-04-03 2008-07-17 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of Breast Cancer
CA2482687C (fr) * 2003-09-29 2012-11-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Traitement du mesotheliome
US7964571B2 (en) * 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
WO2007020509A1 (fr) * 2005-08-15 2007-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Combinaison d'agents de transfert du méthylol et de protéines ou de peptides inhibiteurs de tumeurs, et emploi de ladite combinaison dans le traitement d'un cancer ou d'une croissance tumorale
WO2007077528A1 (fr) * 2006-01-06 2007-07-12 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Compositions irradiees et traitement de cancers avec un rayonnement en combinaison avec la taurolidine et/ou le taurultam
WO2011151722A2 (fr) * 2010-06-01 2011-12-08 Geistlich Pharma Ag Méthodes et compositions de traitement pharmaceutique par voie orale
JP7614714B2 (ja) * 2016-01-11 2025-01-16 コーメディクス・インコーポレーテッド 神経芽細胞腫及びその他のがん治療のための治療ナノ粒子
EP3429614B1 (fr) * 2016-03-18 2023-05-03 Geistlich Pharma AG Méthode de traitement d'un cancer du sein triple négatif
WO2020047113A1 (fr) * 2018-08-28 2020-03-05 Cormedix Inc. Traitement du neuroblastome avec des produits d'hydrolyse de taurolidine

Also Published As

Publication number Publication date
JP2021535167A (ja) 2021-12-16
AU2019331913A1 (en) 2021-04-29
CA3111100A1 (fr) 2020-03-05
AU2019331913B2 (en) 2025-06-26
EP3843747A4 (fr) 2022-12-28
JP2025128194A (ja) 2025-09-02
WO2020047530A1 (fr) 2020-03-05
CN113226325A (zh) 2021-08-06
KR20210054544A (ko) 2021-05-13

Similar Documents

Publication Publication Date Title
US20170266293A1 (en) Methods of treating cancers with therapeutic nanoparticles
JP2024170590A (ja) タウロリジン加水分解産物による神経芽細胞腫治療
Naraharisetti et al. In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma
US20230390300A1 (en) Neuroblastoma treatment with taurolidine hydrolysis products
Wu et al. Cancer Radiosensitization Nanoagent to Activate cGAS‐STING Pathway for Molecular Imaging Guided Synergistic Radio/Chemo/Immunotherapy
US12053478B2 (en) Taurultam, taurinamide and methylene glycol treatment for MYC—expressing tumors in mammalian bodies
US20220323450A1 (en) Methods and compositions for treating neuroblastoma in a juvenile mammalian body
WO2020047530A1 (fr) Traitement à la taurolidine pour des tumeurs exprimant des gènes myc dans des corps de mammifère
JP2009292837A (ja) より効能が大きく副作用の少ない癌治療方法
JP7530351B2 (ja) 若年哺乳動物の身体における神経芽細胞腫を治療するための方法および組成物
CN117083086A (zh) 腺苷二磷酸核糖在放射和／或抗癌治疗辅助疗法中的应用
Akotiah et al. Drug Targeting and Therapeutic Management of Chronic Myeloid Leukemia: Conventional and Nanotherapeutic Drug Options
WO2008135792A1 (fr) Composés pm00104 utilisés en thérapie anticancéreuse
Aktaş et al. Neuroblastoma-targeted Anticancer Drug Delivery
Cui et al. Modest anti-cancer activity of a bile acid acylated heparin derivative in a PC14PE6 induced orthotopic lung cancer model
Soria et al. 421 A Phase Ib study to evaluate the pan-PI3K inhibitor GDC-0941 with paclitaxel and carboplatin with and without bevacizumab in non-small cell lung cancer patients
McMurray et al. 422 Targeting the SH2 domain of Stat3 with phosphopeptide mimetic prodrugs leads to tumor growth inhibition and down-regulation of phosphoTyr705 Stat3 and angiogenic pathways
WO2001000240A2 (fr) Compose antitumoral
WO2008033039A1 (fr) Traitement du cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20210326

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/50 20060101ALI20220727BHEP

Ipc: A61K 38/19 20060101ALI20220727BHEP

Ipc: A61K 31/549 20060101AFI20220727BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20221128

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/50 20060101ALI20221122BHEP

Ipc: A61K 38/19 20060101ALI20221122BHEP

Ipc: A61K 31/549 20060101AFI20221122BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20241128